AcuCort AB (publ) (NGM:ACUC)

Market Cap	176.37M
Revenue (ttm)	7.93M
Net Income (ttm)	-20.31M
Shares Out	226.11M
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	353,794
Average Volume	220,936
Open	0.7480
Previous Close	0.7100
Day's Range	0.6930 - 0.7500
52-Week Range	0.4600 - 1.2600
Beta	1.31
RSI	58.34
Earnings Date	Apr 25, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ACUC

Financial Performance

In 2024, AcuCort AB's revenue was 7.72 million, an increase of 17.07% compared to the previous year's 6.59 million. Losses were -17.40 million, 27.1% more than in 2023.